The FDA will host a conference for medical device manufacturers, health care distributors, group purchasing organizations, hospitals and health care providers, and health care industry professionals.
New York, NY (PRWEB) September 10, 2012
Metal hip systems as well as other high-risk medical devices, such as transvaginal mesh implants, should be the focus of an upcoming conference aimed at providing insight into the U.S. Food and Drug Administration’s (“FDA”) Proposed Regulation to implement unique device identifiers (“UDI”), Bernstein Liebhard LLP reports.* On September 18 and 19, 2012, the FDA will host a conference for medical device manufacturers, health care distributors, group purchasing organizations, hospitals and health care providers, and health care industry professionals who want to understand the newly-released UDI Proposed Regulation, which will “establish a single device identification system that is consistent, unambiguous, standardized, and globally harmonized. All manufacturers of medical devices will be required to comply with the new UDI methodology.”
“Given the known complications associated with certain medical devices such as metal hip systems and transvaginal mesh implants and their dangers to patients, we are heartened to hear of the FDA’s new plan to better track and monitor potentially dangerous devices in the future,” said Bernstein Liebhard LLP, a nationwide law firm representing clients who have been injured by dangerous drugs and defective medical devices. The Firm is currently offering free and confidential case evaluations to individuals who were injured after being implanted with high-risk medical devices.
Purpose Of FDA’s Unique Identification System
As explained more fully in a July 3, 2012 FDA press release on the UDI Proposed Regulation, “A UDI system has the potential to improve the quality of information in medical device adverse event reports, which will help the FDA identify problems more quickly, better target recalls and improve patient safety.”** According to an article published in Bloomberg Businessweek discussing the FDA’s Proposed Regulation, UDIs will help regulators trace:
- product flaws;
- failures; and
The codes will be stored in a public database, which will:
- enable patients to be quickly informed of flaws and dangers; and
- allow companies and hospitals to pull defective devices from the market quickly.***
The lawyers at Bernstein Liebhard LLP are actively representing clients in lawsuits against the manufacturers of defective medical devices in both state and federal courts. Those who have experienced complications from devices such as metal hip systems or transvaginal mesh implants may be entitled to compensation for medical expenses, pain and suffering, lost wages and other injuries. Learn more about your legal rights by visiting our website, http://www.consumerinjurylawyers.com, and by watching these metal hip replacement and transvaginal mesh videos. For more information, contact an attorney at Bernstein Liebhard LLP today at (877) 779-1414.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past nine consecutive years. Only two firms in the country have been selected for the Hot List nine years in a row.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2012 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Amy L. Abate. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
# # #
Felecia L. Stern, Esq.
Bernstein Liebhard LLP